ow-Dose Dasiglucagon for Prevention of Insulin-Induced Hypoglycemia in People with Type 1 Diabetes

Steno Diabetes Center Copenhagen0 个研究点目标入组 20 人开始时间: 2020年3月27日最近更新: 2021年4月5日

适应症

试验速览

暂无简介。

•Age 18-64 years
•Type 1 diabetes = 3 years
•Use of continuous subcutaneous insulin infusion or multiple daily injection therapy for = 6 months
•HbA1c = 8.0%
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 20
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•Use of anti-diabetic medicine (other than insulin), corticosteroids or other drugs affecting glucose metabolism during the study period or within 30 days prior to study start
•History of allergy or intolerance to glucagon or glucagon-like products
•Patients with pheochromocytoma
•Clinically significant ECG abnormalities
•Females who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods (sterilization, intrauterine device, contraceptive pill, patch or injection)
•Inability to understand the individual information and to give informed consent
•Current participation in another clinical trial that, in the judgment of the principle investigator, will compromise the results of the study or the safety of the subject
•Other concomitant medical or psychological condition that, according to the investigator's assessment, makes the individual unsuitable for study participation

发起方